Israeli Can-Fite gets US patent for experimental drug
Last Modified: 07:15 AM, Mon May 25, 2020
SeeNews Pharmaceuticals. 25 May 2020

Word Count: 124

May 25 (SeeNews) - Israeli biotechnology firm Can-Fite Biopharma (TLV:CANF) on Thursday said it has obtained a US patent for a method of treating fatty liver disease with its experimental drug namodenoson.

The patent was granted based onpromising Phase II trial data. The trial assessed the drug in patients with non-alcoholic fatty liver disease, some of whom had developed a more aggressive form known as non-alcoholic steatohepatitis (NASH) that is characterised by liver inflammation and may progress to liver failure.

According to the data, the drug resolved all cases of NASH after 12 weeks of treatment and reduced scarring of the liver and fat accumulation in fatty liver disease and NASH patients.

Powered by InfoDesk
RIS
InfoDesk Inc
Article Info
Dateline: Monday, May 25
Publication: SeeNews Pharmaceuticals
Location: Israel, United States
Industry: Pharmaceuticals, Health Care/Life Sciences
Topics
New Product/Service Testing, Patents, Intellectual Property Rights, New Products/Services, Research/Development, Corporate/Industrial News, Products/Services, Industrial Property Rights